Ophthalmologist Salary Guide 2026: Retina, Cataract, LASIK & Anti-VEGF Revenue

Ophthalmology has one of the most unusual compensation structures in all of medicine, with income driven by three largely independent revenue streams: surgical case volume (cataract and vitreoretinal surgery), intravitreal anti-VEGF injection buy-and-bill (the dominant income source for retina specialists), and elective refractive surgery (cash-pay LASIK and premium intraocular lens programs). In 2026, general ophthalmologists in employed settings earn $280,000–$420,000, while high-volume retina practices and busy LASIK centers can produce physician income well above $1,000,000. This guide covers salary benchmarks by subspecialty, the economics of anti-VEGF drug revenue, cataract ASC ownership, and the premium IOL and refractive revenue model.

Ophthalmologist salary by subspecialty

• Retina specialist / vitreoretinal surgeon: $550,000–$950,000+; the highest-paid ophthalmology subspecialty in most markets; income driven by intravitreal anti-VEGF injection volume and retinal surgery (vitrectomy, retinal detachment repair, epiretinal membrane peel, macular hole repair); busy retina practices with 40–80 injections/day have physician income exceeding $1,000,000 after drug margin, surgical fees, and ASC distributions
• Comprehensive ophthalmologist / cataract surgeon (private practice): $380,000–$650,000; general ophthalmology with cataract surgery as the primary surgical procedure; high-volume cataract surgeons performing 20–40 cases/week at physician-owned ASCs generate significant facility fee income; premium IOL upcharges (toric, multifocal, extended depth of focus) add direct-pay revenue above insurance-covered services
• LASIK / refractive surgery specialist: $400,000–$800,000; primarily cash-pay LASIK, PRK, SMILE, LASEK; premium pricing ($2,000–$4,000/eye in most markets); some refractive surgeons also perform refractive lens exchange (RLE) and cataract surgery with premium IOL; overhead-intensive (LASIK equipment requires $400,000–$600,000 investment) but high margin at volume
• Glaucoma specialist: $350,000–$600,000; medical glaucoma management, laser trabeculoplasty (SLT), MIGS (minimally invasive glaucoma surgery — iStent, Kahook dual blade, OMNI, Hydrus), trabeculectomy, tube shunt surgery; MIGS procedures are typically done at time of cataract surgery (CPT 0671T–0673T) and add incremental billing
• Cornea and external disease specialist: $320,000–$550,000; DMEK/DSEK corneal transplantation, keratoconus management (corneal cross-linking), anterior segment reconstruction, dry eye disease management; dry eye treatment technology (LipiFlow, IPL, punctal plugs) adds in-office procedural revenue
• Oculoplastics / orbital surgery: $320,000–$560,000; eyelid surgery (ptosis repair, blepharoplasty), lacrimal surgery (DCR), orbital fracture repair, enucleation, orbital tumor; cosmetic blepharoplasty adds significant direct-pay revenue for oculoplastic surgeons willing to mix cosmetic and functional cases
• Pediatric ophthalmology: $260,000–$420,000; strabismus surgery, amblyopia management, retinopathy of prematurity (ROP) screening and laser treatment, pediatric cataract; children's hospital and academic center concentration; lower income than adult subspecialties
• Neuro-ophthalmology: $280,000–$430,000; optic neuritis, papilledema, visual field defects, cranial nerve palsies, orbital tumors; predominantly cognitive with minimal procedures; academic and neurology-affiliated practice models
• Academic ophthalmology: $250,000–$400,000; medical school faculty; ophthalmology residency training; NIH-funded vision research (glaucoma, macular degeneration, diabetic eye disease); lower nominal pay offset by research time and subspecialty expertise development

Anti-VEGF injection buy-and-bill economics

Intravitreal anti-VEGF injection for age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion is the single largest revenue mechanism in ophthalmology. Understanding the economics separates the highest-earning retina practices from average ones:

• Bevacizumab (Avastin, off-label compounded): Acquisition cost $50–$80 per compounded dose; reimbursement similar to compounded drug billing; very low drug margin but maintains patient volume; used by practices managing high Medicaid/uninsured population where branded drugs are cost-prohibitive
• Ranibizumab (Lucentis, biosimilar Byooviz, Cimerli): Biosimilar entry has reduced prices significantly from the original $1,200–$2,000 range; biosimilar ranibizumab acquisition typically $400–$700; reimbursement at ASP + markup; growing biosimilar adoption
• Aflibercept (Eylea, biosimilar Yesafili, Opuviz): Most widely used anti-VEGF in the U.S.; original Eylea ASP $1,500–$2,000 per vial; Eylea HD (high-dose, 8 mg) launched 2023 at premium price point; biosimilar entry underway; each injection generates $150–$500 in drug margin depending on drug choice, payer, and contract
• Faricimab (Vabysmo): Bispecific anti-VEGF/Ang-2 from Genentech; $2,200+ per dose; extended dosing intervals (up to 16 weeks) a selling point; premium drug choice with higher acquisition cost and variable payer coverage
• Practice revenue scale: A busy retina practice administering 50 intravitreal injections/day × 240 clinic days × $200 average net drug margin = $2,400,000/year in drug margin alone — before surgical case fees, facility fees, or E&M billing; this is why retina is consistently the highest-earning ophthalmology subspecialty

Cataract surgery ASC economics and premium IOLs

Cataract surgery is the highest-volume surgical procedure in the United States, and the ASC model is central to the financial performance of comprehensive ophthalmology practices:

• Cataract ASC facility fee: Medicare rates for cataract surgery at ASC are $1,000–$1,500; commercial payers pay $1,500–$3,500 per eye; each case generates a facility fee in addition to the physician's professional fee ($500–$900); a high-volume ophthalmologist performing 30 cataract cases/week at a physician-owned ASC generates $2,000,000–$4,000,000+ in annual ASC facility fee revenue at their ownership percentage
• Premium IOL revenue: Standard monofocal IOLs are covered by Medicare/insurance; premium IOLs (toric for astigmatism correction, multifocal, extended depth of focus — EDOF) are covered only for the base monofocal component; patients pay $1,500–$3,500 per eye in cash for the premium IOL upgrade; practices with strong premium IOL conversion rates (30–50% of cataract patients choosing premium) generate substantial additional direct-pay revenue
• MIGS combined with cataract: Minimally invasive glaucoma surgery (iStent inject, Kahook dual blade, OMNI) performed at time of cataract surgery generates additional CPT code billing; MIGS adds $400–$1,200 per procedure to the cataract surgical billing

LASIK and refractive surgery revenue model

Laser refractive surgery is one of the most distinct revenue models in ophthalmology — almost entirely direct-pay with minimal insurance involvement:

• LASIK pricing: $2,000–$4,000 per eye in most U.S. markets; metropolitan markets with high cosmetic competition at the lower end; specialty/premium markets (blade-free all-laser, wavefront-guided, SMILE) at the higher end; military, physician group discounts, and financing all affect net revenue per case
• Case volume at scale: A LASIK center performing 300 bilateral cases/month at $2,500/eye net = $750,000/month in surgical revenue; center overhead (equipment service, laser per-use fees, excimer laser costs), technician staffing, and marketing reduce net to the physician owner
• Refractive lens exchange (RLE): Lens-based refractive surgery for patients over 45 with presbyopia or high refractive error; $4,000–$7,000/eye direct-pay; higher margin than LASIK; growing segment as premium IOL awareness increases

Geographic variation in ophthalmology compensation

• Sun Belt (FL, TX, AZ): $420,000–$900,000+; large aging population with high AMD, diabetic eye disease, and cataract burden; strong private practice culture; retina demand especially high in FL and TX markets
• Northeast / coastal metros: $380,000–$750,000; academic center presence; refractive surgery demand in affluent urban markets; commercial payer mix favorable for anti-VEGF billing
• Midwest: $330,000–$650,000; multispecialty group practices and academic centers anchor the market; community ophthalmology demand consistent
• Rural / shortage markets: $320,000–$580,000; significant ophthalmology access gaps in rural areas; some rural hospitals recruiting general ophthalmologists with significant sign-on to establish local access to basic eye care and cataract surgery

What we see at Ava Health

Ophthalmology is a specialty where the private practice vs. employed income gap is extraordinarily large — the anti-VEGF injection buy-and-bill model and cataract ASC ownership create income that health system employed ophthalmologists simply cannot access. For retina fellows and comprehensive ophthalmology residents in our network evaluating their first attending position, understanding whether a practice has an established injection clinic and the patient volume to sustain high injection days is the single most important financial evaluation — more important than base salary, which is a relatively small fraction of total income for high-volume retina specialists.

Related: Orthopedic Surgeon Salary Guide, Dermatologist Salary Guide, Neurosurgeon Salary Guide, Plastic Surgeon Salary Guide.